Bao Shi-Ting, Gui Shui-Qing, Lin Mu-Sheng
Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China.
Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):580-3.
The second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) was recently identified as a protein that is released from mitochondria in response to apoptotic stimuli and promotes apoptosis by antagonizing inhibitor of apoptosis proteins. Furthermore, Smac/DIABLO plays an important regulatory role in the sensitization of cancer cells to both immune- and drug-induced apoptosis. However, little is known about the clinical significance of Smac/DIABLO in various cancers including hepatocellular carcinoma (HCC). This study was undertaken to investigate the expression of Smac and Survivin and their relationship with the apoptosis in primary HCC.
The expression of Smac and Survivin proteins was evaluated by immunohistochemistry. The mRNA expression of Smac and Survivin was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) in HCC tissues of 50 patients, para-carcinoma tissues of 20 patients, and normal liver tissues of 15 patients.
Smac mRNA was detected by RT-PCR in HCC tissues of 21 (42.0%) of the 50 patients, para-carcinoma tissues of 19 (95.0%) of the 20 patients, and normal liver tissues of 15 (100%) of the 15 patients. Survivin mRNA was found in HCC tissues of 46 of the 50 patients, para-carcinoma tissues of 2 of the 20 patients, and normal liver tissues of 0 of 15 patients. Immunohistochemistry revealed Smac protein in HCC tissues of 20 patients (40.0%), in para-carcinoma tissues of 18 patients (90.0%), and normal liver tissues of 15 patients (100.0%). The expression of Smac was significantly different in HCC tissues and non-HCC tissues. Survivin protein was found in HCC tissues in 45 patients, para-carcinoma tissues in 2 patients, and normal liver tissues in none of the patients. The expression of Survivin was significantly different in HCC tissues and non-HCC tissues.
Smac inhibits apoptosis of HCC cells by suppression of Survivin, and the two genes probably form an important link in the signal pathway of HCC cells.
第二线粒体衍生的半胱天冬酶激活剂/低等电点凋亡抑制蛋白结合直接抑制剂(Smac/DIABLO)最近被鉴定为一种蛋白质,它在凋亡刺激下从线粒体释放,并通过拮抗凋亡抑制蛋白来促进凋亡。此外,Smac/DIABLO在癌细胞对免疫诱导和药物诱导凋亡的敏感性中发挥重要调节作用。然而,关于Smac/DIABLO在包括肝细胞癌(HCC)在内的各种癌症中的临床意义知之甚少。本研究旨在探讨原发性肝癌中Smac和Survivin的表达及其与凋亡的关系。
采用免疫组织化学法评估Smac和Survivin蛋白的表达。采用逆转录-聚合酶链反应(RT-PCR)检测50例肝癌组织、20例癌旁组织和15例正常肝组织中Smac和Survivin的mRNA表达。
RT-PCR检测发现,50例患者中的21例(42.0%)肝癌组织、20例患者中的19例(95.0%)癌旁组织和15例患者中的15例(100%)正常肝组织中可检测到Smac mRNA。50例患者中的46例肝癌组织、20例患者中的2例癌旁组织和15例患者中的0例正常肝组织中可检测到Survivin mRNA。免疫组织化学显示,20例(40.0%)肝癌组织、18例(90.0%)癌旁组织和15例(100.0%)正常肝组织中存在Smac蛋白。Smac在肝癌组织和非肝癌组织中的表达有显著差异。45例肝癌组织、2例癌旁组织中可检测到Survivin蛋白,正常肝组织中未检测到。Survivin在肝癌组织和非肝癌组织中的表达有显著差异。
Smac通过抑制Survivin抑制肝癌细胞凋亡,这两个基因可能在肝癌细胞信号通路中形成重要联系。